In a new note to investors yesterday, an analyst has provided a rating update for the Consumer Goods sector company, Irwin Naturals Inc (IWIN – Research Report). Analyst Michael Okunewitch from Maxim Group remains bullish on the stock.
According to TipRanks.com, Okunewitch has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -31.6% and a 11.8% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as BioRestorative Therapies, Citius Pharmaceuticals, and Kiora Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Irwin Naturals Inc.
Irwin Naturals Inc is a nutraceutical company that distributes dietary supplements to more than 100,000 retailers, including mass-market retailers.
The company’s shares closed yesterday at C$1.19.
Read More on TSE:IWIN:
- Irwin Naturals price target lowered to $3.00 from $4.50 at Roth MKM
- Irwin Naturals reports Q2 EPS ($1.57) vs. 0c last year
- Irwin Naturals Reports Q2 2023 Financial Results
- Irwin Naturals Unleashes Trio of Cannabis Tinctures in Golden State
- Irwin Naturals enters California market with trio of cannabis tinctures
